Assessment of the substrate for atrial fibrillation using tissue velocity imaging of the fibrillating wall

Completed

• Conditions: atrial fibrillation; 10007521

• Registration Number: NL-OMON36728
• Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 229

Inclusion Criteria

Patients with acute paroxysmal AF referred for pharmacological cardioversion or patients with
persistent AF referred for electrical cardioversion.

Exclusion Criteria

- <18 years, permanent AF
- patients with a clinical contra-indication for flecainide, ibutilide or amiodarone (including
pregnancy)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint:<br /><br>persistent AF during one year follow-up.<br /><br></p><br>

Secondary Outcome Measures

Name	Time	Method
<p>(a) conversion to sinus rhythm<br /><br>(b) serial AFCL-TVI and AFV-TVI assessments completed<br /><br>(c) development of persistent AF on amiodarone<br /><br>(d) development of persistent AF or major adverse cardiovascular or<br /><br>cerebrovascular events during 3-5 years follow-up.</p><br>